Mayo Clinic | Strategic Alliance Partners

Latest from Mayo Clinic


Mayo Researchers: Change NCCN Criteria to Expand Genetic Testing in Breast Cancer

March 06, 2020

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.

ELAINE Trial Explores Lasofoxifene in ESR1+ Breast Cancer

December 18, 2019

Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.

PARP Inhibitors Gain a Foothold in Prostate Cancer

December 12, 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.